ATE523602T1 - Mit durch antipsychotika induzierten extrapyramidalen symptomen assoziierte rgs2- genotypen - Google Patents

Mit durch antipsychotika induzierten extrapyramidalen symptomen assoziierte rgs2- genotypen

Info

Publication number
ATE523602T1
ATE523602T1 AT07736444T AT07736444T ATE523602T1 AT E523602 T1 ATE523602 T1 AT E523602T1 AT 07736444 T AT07736444 T AT 07736444T AT 07736444 T AT07736444 T AT 07736444T AT E523602 T1 ATE523602 T1 AT E523602T1
Authority
AT
Austria
Prior art keywords
extrapyramidal symptoms
rgs2
antipsychotics
genotypes associated
symptoms induced
Prior art date
Application number
AT07736444T
Other languages
English (en)
Inventor
Bernard Lerer
Lior Greenbaum
Original Assignee
Hadasit Med Res Service
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hadasit Med Res Service filed Critical Hadasit Med Res Service
Application granted granted Critical
Publication of ATE523602T1 publication Critical patent/ATE523602T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT07736444T 2006-06-12 2007-06-12 Mit durch antipsychotika induzierten extrapyramidalen symptomen assoziierte rgs2- genotypen ATE523602T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81259906P 2006-06-12 2006-06-12
PCT/IL2007/000704 WO2007144874A1 (en) 2006-06-12 2007-06-12 Rgs2 genotypes associated with extrapyramidal symptoms induced by antipsychotic medication

Publications (1)

Publication Number Publication Date
ATE523602T1 true ATE523602T1 (de) 2011-09-15

Family

ID=38461906

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07736444T ATE523602T1 (de) 2006-06-12 2007-06-12 Mit durch antipsychotika induzierten extrapyramidalen symptomen assoziierte rgs2- genotypen

Country Status (4)

Country Link
US (2) US20100021891A1 (de)
EP (1) EP2041304B1 (de)
AT (1) ATE523602T1 (de)
WO (1) WO2007144874A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE523602T1 (de) * 2006-06-12 2011-09-15 Hadasit Med Res Service Mit durch antipsychotika induzierten extrapyramidalen symptomen assoziierte rgs2- genotypen
WO2011148379A2 (en) * 2010-05-27 2011-12-01 Hadasit Medical Research Services And Development Ltd. Antipsychotic-induced parkinsonism genotypes and methods of using same
US20130080182A1 (en) * 2011-09-26 2013-03-28 Athleticode Inc. Methods For Using DNA Testing To Screen For Genotypes Relevant To Athleticism, Health And Risk Of Injury
BR112015017815B1 (pt) * 2013-01-25 2022-06-14 Institut D'investigacions Biomèdiques August Pi I Sunyer Método para prever o início dos sintomas extrapiramidais (eps) induzidos por um tratamento a base de antipsicótico
US10036247B2 (en) * 2015-11-16 2018-07-31 Baker Hughes, A Ge Company, Llc Downhole fiber optic measurement of packers during fluid injection operations

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3539573A (en) * 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
US4086350A (en) * 1974-11-06 1978-04-25 Smithkline Corporation Pharmaceutical compositions and method of producing anti-psychotic activity without extrapyramidal symptoms
US4458066A (en) * 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
IE58370B1 (en) * 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
US5348855A (en) * 1986-03-05 1994-09-20 Miles Inc. Assay for nucleic acid sequences in an unpurified sample
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
DE68928853T2 (de) 1988-05-20 1999-08-05 Cetus Corp., Emeryville, Calif. Befestigung von sequenzspezifischen proben
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
US5238945A (en) * 1989-04-11 1993-08-24 H. Lundbeck A/S Method of treating psychoses
GB8908085D0 (en) * 1989-04-11 1989-05-24 Lundbeck & Co As H New therapeutic use
US5500343A (en) * 1990-02-07 1996-03-19 Board Of Regents, The University Of Texas System Allelic association of the human dopamine(D2) receptor gene in compulsive disorders
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5137712A (en) * 1990-08-31 1992-08-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of s-adenosyl-l-methionine (SAMe) to reverse and/or prevent supersensitivity, tolerance and extrapyramidal side effects induced by neuroleptic treatment
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5593840A (en) * 1993-01-27 1997-01-14 Oncor, Inc. Amplification of nucleic acid sequences
US5324401A (en) * 1993-02-05 1994-06-28 Iowa State University Research Foundation, Inc. Multiplexed fluorescence detector system for capillary electrophoresis
US6951721B2 (en) * 1996-02-12 2005-10-04 Gene Logic Inc. Method for determining the haplotype of a human BRCA1 gene
US6844154B2 (en) * 2000-04-04 2005-01-18 Polygenyx, Inc. High throughput methods for haplotyping
AU2001255448A1 (en) 2000-04-17 2001-10-30 Stephen B. Liggett Alpha-2 adrenergic receptor polymorphisms
MY129350A (en) * 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
EP1425023A1 (de) * 2001-08-10 2004-06-09 Wyeth G-proteingekoppelter rezeptor-assay
EP1692503B1 (de) 2003-10-17 2009-09-30 Tata Institute of Fundamental Research Neuer test zum screening von antipsychotika
ATE523602T1 (de) 2006-06-12 2011-09-15 Hadasit Med Res Service Mit durch antipsychotika induzierten extrapyramidalen symptomen assoziierte rgs2- genotypen
US20090307180A1 (en) 2008-03-19 2009-12-10 Brandon Colby Genetic analysis

Also Published As

Publication number Publication date
US20100021891A1 (en) 2010-01-28
EP2041304B1 (de) 2011-09-07
US8986929B2 (en) 2015-03-24
US20110236896A1 (en) 2011-09-29
EP2041304A1 (de) 2009-04-01
WO2007144874A1 (en) 2007-12-21

Similar Documents

Publication Publication Date Title
NZ600235A (en) Methods and compositions for the assessment of drug response
Hejjas et al. Association between depression and the Gln460Arg polymorphism of P2RX7 gene: a dimensional approach
AR065910A1 (es) Marcadores biologicos pronosticos de la respuesta de la artritis reumatoide a los antagonistas de los linfocitos b
WO2010018601A3 (en) Genetic variants predictive of cancer risk
MX2009012722A (es) Variantes geneticas sobre chr 5p12 y 10q26 como marcadores para el uso en la evaluacion del riesgo, diagnostico, pronostico y tratamiento del cancer de mama.
EP2310525A4 (de) Mit herz-kreislauf-erkrankungen assoziierte genetische polymorphismen, nachweisverfahren und ihre verwendung
EP2064345A4 (de) Psorase-assoziierte genetische polymorphien, nachweisverfahren dafür und ihre verwendung
WO2010060996A3 (en) Prediction of lipid-metabotype-related physiological susceptibilities
WO2008151803A3 (en) New polymorphisms in abcb1 associated with a lack of clinical response to medicaments
WO2010004591A3 (en) Genetic variants for breast cancer risk assessment
WO2008132763A3 (en) Genetic variants useful for risk assessment of coronary artery disease and myocardial infarction
RU2015143177A (ru) Анализы и способы выбора схемы лечения для субъекта с депрессией
MX2010005060A (es) Identificacion y mapeo a base de microarreglos de adn de puntos de ruptura de translocacion equilibrados.
ATE523602T1 (de) Mit durch antipsychotika induzierten extrapyramidalen symptomen assoziierte rgs2- genotypen
WO2007028162A3 (en) Methods and compositions for identifying biomarkers useful in diagnosis and/or treatment of biological states
GB201121917D0 (en) Genetic analysis to determine ingredient efficacy
EP2041338A4 (de) Interferon-gamma-polymorphismen als indikatoren des patientenergebnisses bei schwerkranken patienten
WO2008076856A3 (en) Reagents and methods for detecting cyp2d6 polymorphisms
DK1730315T3 (da) Polymorphismer i NOD2/Card15 gen
WO2009060210A8 (en) Predictive test for adult dog body size
GB0713364D0 (en) Abnormal blood conditions
AR095658A1 (es) Método para la predicción de los síntomas extrapiramidales (sep) inducidos por un tratamiento basado en antipsicóticos
Lee et al. No association between AKT1 polymorphism and schizophrenia: A case–control study in a Korean population and a meta-analysis
CA2686874C (en) Polymorphism in the apo(a) gene predict responsiveness to acetylsalicylic acid treatment
EE200700019A (et) Meetod ja komplekt inimese kindlakstegemiseks, kellel on geneetiline eelsoodumus ssivesikute liigtarbimiseks

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties